Scholarlink

<p>Extended-spectrum beta-lactamase (ESBL) and ampicillin resistance gene type C (ampC) in foodborne <i>Citrobacter freundii (C. freundii)</i> pose a severe public health risk, especially when they combine with other critical resistance genes to produce a reservoir of resistance. Therefore, the current study aimed to estimate the prevalence, phenotypic, and genotypic profiling of antimicrobial resistance in <i>C. freundii</i> isolates obtained from diseased broiler chickens and native Egyptian buffaloes in Kafr El-Sheikh and Dakahlia governorates, Egypt. Also, the investigation of the antibacterial activity of chitosan (CS) 1%, 2%, and chitosan nanoparticles (CSNPs), including the estimation of minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) and their combinations with ciprofloxacin (CIP), were evaluated. <i>C. freundii</i> was detected in 57.58% (19/33) of broiler chickens and 52.63% (20/38) of buffalo. Surprisingly, 26.32% (5/19) and 20% (4/20) of chicken and buffalo samples, respectively were multidrug-resistant (MDR), 42.11% (8/19) and 15% (3/20) were extensively drug-resistant (XDR), and 31.58% (6/19) and 65% (13/20) were pan drug-like-resistant (PDR). High frequencies of resistance genes were observed, including <i>int</i>1, <i>dfrA</i>1, <i>sul</i>2, <i>aad</i>A1, <i>qnr</i>A, and <i>bla</i><sub>TEM</sub> (≥ 80%), while other genes such as <i>erm</i>B, <i>bla</i><sub>CMY−2</sub>, <i>bla</i><sub>OXA−10</sub>, <i>tet</i>(M), <i>mcr-</i>1, <i>bla</i><sub>CTX−M,</sub> and <i>cat</i>A1 were detected at variable rates. Alarmingly, all ESBL/AmpC-producing isolates co-harbored multiple critical resistance genes. CSNPs showed markedly lower MIC and MBC values compared with 1% and 2% CS, indicating significantly stronger bactericidal activity. The concerning prevalence of PDR like-<i>C. freundii</i> in food animals is brought to light by our results, which also provide credence to the use of 2% CS–CIP and CSNPs–CIP combinations as potential substitute treatments for resistant infections.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chitosan mitigates pan drug resistance in citrobacter freundii exhibiting AmpC and ESBL from Egyptian livestock

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月5日

查看全文
  • Ibtisam Faeq Hasona,
  • Gamal Younis,
  • Amal Awad

摘要

Extended-spectrum beta-lactamase (ESBL) and ampicillin resistance gene type C (ampC) in foodborne Citrobacter freundii (C. freundii) pose a severe public health risk, especially when they combine with other critical resistance genes to produce a reservoir of resistance. Therefore, the current study aimed to estimate the prevalence, phenotypic, and genotypic profiling of antimicrobial resistance in C. freundii isolates obtained from diseased broiler chickens and native Egyptian buffaloes in Kafr El-Sheikh and Dakahlia governorates, Egypt. Also, the investigation of the antibacterial activity of chitosan (CS) 1%, 2%, and chitosan nanoparticles (CSNPs), including the estimation of minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) and their combinations with ciprofloxacin (CIP), were evaluated. C. freundii was detected in 57.58% (19/33) of broiler chickens and 52.63% (20/38) of buffalo. Surprisingly, 26.32% (5/19) and 20% (4/20) of chicken and buffalo samples, respectively were multidrug-resistant (MDR), 42.11% (8/19) and 15% (3/20) were extensively drug-resistant (XDR), and 31.58% (6/19) and 65% (13/20) were pan drug-like-resistant (PDR). High frequencies of resistance genes were observed, including int1, dfrA1, sul2, aadA1, qnrA, and blaTEM (≥ 80%), while other genes such as ermB, blaCMY−2, blaOXA−10, tet(M), mcr-1, blaCTX−M, and catA1 were detected at variable rates. Alarmingly, all ESBL/AmpC-producing isolates co-harbored multiple critical resistance genes. CSNPs showed markedly lower MIC and MBC values compared with 1% and 2% CS, indicating significantly stronger bactericidal activity. The concerning prevalence of PDR like-C. freundii in food animals is brought to light by our results, which also provide credence to the use of 2% CS–CIP and CSNPs–CIP combinations as potential substitute treatments for resistant infections.